In:
RETINAL Cases & Brief Reports, Ovid Technologies (Wolters Kluwer Health), Vol. 11, No. 1 ( 2017), p. 38-43
Abstract:
To present a case of partially reversible retinal toxicity related to a newer epilepsy medication, ezogabine (Potiga). Methods: Case report with multimodal imaging. Patient: A patient presented 9 months after starting ezogabine for a screening eye examination with new retinal pigment abnormalities in the maculas of both eyes. Results: These macular abnormalities are characterized for the first time with multimodal imaging. They were partially reversible after cessation of the drug. Conclusion: Ezogabine toxicity presents as pigmentary changes in the macula on fundus examination and has newly described characteristics on imaging that can guide ophthalmologists when they perform the FDA-recommended 6-month screening visits for ocular toxicity.
Type of Medium:
Online Resource
ISSN:
1935-1089
DOI:
10.1097/ICB.0000000000000283
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2017
